New hope for liver cancer patients when standard treatments fail
NCT ID NCT07184424
Summary
This study looked at whether adding the drug lenalidomide could help control advanced liver cancer in patients whose cancer had continued to grow despite receiving standard treatments. Researchers observed 24 patients who had previously received lenvatinib and PD-1 inhibitor therapy but experienced disease progression. The study collected real-world data to see if the three-drug combination could help slow cancer growth and extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.